Details for New Drug Application (NDA): 215974
✉ Email this page to a colleague
NDA 215974 describes SUNLENCA, which is a drug marketed by Gilead Sciences Inc and is included in two NDAs. It is available from one supplier. There are five patents protecting this drug. Additional details are available on the SUNLENCA profile page.
The generic ingredient in SUNLENCA is lenacapavir sodium. One supplier is listed for this compound. Additional details are available on the lenacapavir sodium profile page.
The generic ingredient in SUNLENCA is lenacapavir sodium. One supplier is listed for this compound. Additional details are available on the lenacapavir sodium profile page.
Summary for 215974
| Tradename: | SUNLENCA |
| Applicant: | Gilead Sciences Inc |
| Ingredient: | lenacapavir sodium |
| Patents: | 5 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 215974
Generic Entry Date for 215974*:
Constraining patent/regulatory exclusivity:
NEW CHEMICAL ENTITY Dosage:
TABLET;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Pharmacology for NDA: 215974
Suppliers and Packaging for NDA: 215974
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| SUNLENCA | lenacapavir sodium | TABLET;ORAL | 215974 | NDA | Gilead Sciences | 61958-3001 | 61958-3001-1 | 1 POUCH in 1 CARTON (61958-3001-1) / 1 BLISTER PACK in 1 POUCH / 4 TABLET, FILM COATED in 1 BLISTER PACK |
| SUNLENCA | lenacapavir sodium | TABLET;ORAL | 215974 | NDA | Gilead Sciences | 61958-3001 | 61958-3001-2 | 1 POUCH in 1 CARTON (61958-3001-2) / 1 BLISTER PACK in 1 POUCH / 5 TABLET, FILM COATED in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | TABLET;ORAL | Strength | EQ 300MG BASE | ||||
| Approval Date: | Dec 22, 2022 | TE: | RLD: | Yes | |||||
| Regulatory Exclusivity Expiration: | Dec 22, 2027 | ||||||||
| Regulatory Exclusivity Use: | NEW CHEMICAL ENTITY | ||||||||
| Patent: | 10,071,985 | Patent Expiration: | Aug 17, 2037 | Product Flag? | Y | Substance Flag? | Y | Delist Request? | |
| Patent: | 10,654,827 | Patent Expiration: | Aug 17, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | IN COMBINATION WITH OTHER ANTIRETROVIRAL(S), FOR THE TREATMENT OF HIV-1 INFECTION IN HEAVILY-TREATMENT EXPERIENCED ADULTS WITH MULTIDRUG RESISTANT HIV-1 INFECTION | ||||||||
Complete Access Available with Subscription
